Akero Therapeutics, Inc. AKRO · Stock Open Akero Therapeutics, Inc. in new tab
Akero Therapeutics, Inc. Analysis (AKRO)
Is Akero Therapeutics, Inc. a good investment? Akero Therapeutics, Inc. (AKRO) is currently trading at 54.65 USD. Market analysts have a consensus price target of 56.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: Akero Therapeutics, Inc. is expected to release its next earnings report on Feb. 27, 2026. The market consensus estimate for Forward EPS is -4.01.
Investor FAQ
Does Akero Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Akero Therapeutics, Inc.?
Akero Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Feb. 27, 2026. The company currently has a trailing EPS of -3.75.
Company Profile
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.
Community Discussion